<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171013</url>
  </required_header>
  <id_info>
    <org_study_id>1160.56</org_study_id>
    <nct_id>NCT02171013</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers</brief_title>
  <official_title>Bioequivalence of Two Different Drug Product Batches of 150 mg of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double Blind, Randomised, Single-dose, Replicate Design in a Two-treatments, Four Periods Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To establish the bioequivalence of two drug product batches of dabigatran etexilate, one
      batch containing only polymorph I vs. the other batch containing 17% of dabigatran etexilate
      polymorph II in addition to polymorph I
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of total BIBR 953 ZW in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of total BIBR 953 ZW in plasma (Cmax)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of free BIBR 953 ZW in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of free BIBR 953 ZW in plasma (Cmax)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve of the analyte in plasma over the time interval t1 to t2 (AUCt1-t2)</measure>
    <time_frame>t1 = 0 and t2 = 24, 48, 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of the analyte in plasma (tmax)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant in plasma (λz)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after oral administration (MRTpo)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in the plasma after extravascular administration (CL/F )</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>Up to 72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physical examination</measure>
    <time_frame>Baseline, day 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>Baseline, day 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 12-lead ECG (electrocardiogram)</measure>
    <time_frame>Baseline, day 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in clinical laboratory tests</measure>
    <time_frame>Baseline, day 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Up to day 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a four point scale (good, satisfactory, not satisfactory, bad)</measure>
    <time_frame>Day 73</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate batch A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate batch B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)</intervention_name>
    <arm_group_label>Dabigatran etexilate batch A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran polymorph I</intervention_name>
    <arm_group_label>Dabigatran etexilate batch B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females according to the following criteria: Based upon a complete
             medical history, including the physical examination, vital signs (BP, PR), 12-lead
             ECG, clinical laboratory tests

          2. Age ≥65 and ≤85 years

          3. BMI ≥18.5 and BMI ≤32.0 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion Criteria:

          1. Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological or hormonal disorders

          2. Clinically relevant surgery of gastrointestinal tract

          3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          4. Any relevant bleeding history

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          8. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

         10. Participation in another trial with an investigational drug within four weeks prior to
             administration or during the trial

         11. Alcohol abuse (more than 60 g/day)

         12. Drug abuse

         13. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         14. Excessive physical activities (within one week prior to administration or during the
             trial)

         15. Any laboratory value outside the reference range that is of clinical relevance

         16. Inability to comply with dietary regimen of study centre
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

